Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HALO
DateTimeSourceHeadlineSymbolCompany
03/12/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
03/12/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/11/202413:30PR Newswire (US)Halozyme to Present at Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
22/11/202413:35PR Newswire (US)Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsNASDAQ:HALOHalozyme Therapeutics Incorporated
14/11/202421:15PR Newswire (US)Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash TransactionNASDAQ:HALOHalozyme Therapeutics Incorporated
12/11/202414:36Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
31/10/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
31/10/202420:01PR Newswire (US)HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
24/10/202410:30PR Newswire (US)HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPENASDAQ:HALOHalozyme Therapeutics Incorporated
23/10/202420:30PR Newswire (US)Halozyme to Report Third Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202422:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202420:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
15/10/202420:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/10/202412:09InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor UseNASDAQ:HALOHalozyme Therapeutics Incorporated
09/10/202421:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/10/202420:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
08/10/202420:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
03/10/202412:00PR Newswire (US)Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®NASDAQ:HALOHalozyme Therapeutics Incorporated
26/09/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
26/09/202420:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
25/09/202420:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
24/09/202420:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
18/09/202422:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
18/09/202420:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
17/09/202420:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
13/09/202417:30PR Newswire (US)Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple SclerosisNASDAQ:HALOHalozyme Therapeutics Incorporated
13/09/202400:00PR Newswire (US)Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of CancerNASDAQ:HALOHalozyme Therapeutics Incorporated
12/09/202421:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
12/09/202420:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
11/09/202420:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Your Recent History

Delayed Upgrade Clock